Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Clinical & Experimental Metastasis|November 26, 2013
RANK expression on breast cancer cells promotes skeletal metastasisMichelle L Blake, Mark Tometsko, Robert Miller, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 6, 2014
RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastasesRobert E Miller, Jon C Jones, Mark Tometsko, et al.
Molecular and Cellular Biology|December 6, 2006
RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial aciniEva Gonzalez-Suarez, Daniel Branstetter, Allison Armstrong, et al.
Advances in Experimental Medicine and Biology|October 31, 2007
RANKL inhibition: from mice to men (and women)Marina Stolina, Paul J Kostenuik, William C Dougall, et al.
Molecular Cancer Therapeutics|July 9, 2008
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasisRobert E Miller, Martine Roudier, Jon Jones, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|July 12, 2005
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bonePeter G Whang, Edward M Schwarz, Seth C Gamradt, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|March 2, 2017
Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical MethodClive R Taylor, Daniel Branstetter, Edward Manna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2016
Molecular Pathways: Targeting CD96 and TIGIT for Cancer ImmunotherapyStephen J Blake, William C Dougall, John J Miles, et al.
Cancer Biology & Therapy|February 13, 2010
Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasisPamela M Holland, Robert Miller, Jon Jones, et al.
The Journal of Biological Chemistry|August 20, 2002
A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive functionAllison P Armstrong, Mark E Tometsko, Moira Glaccum, et al.
Pageof 7